Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Gross Margin: 2022-2025

Historic Gross Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to 94.31%.

  • Orchestra BioMed Holdings' Gross Margin rose 120.00% to 94.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.01%, marking a year-over-year increase of 30.00%. This contributed to the annual value of 92.27% for FY2024, which is 99.00% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Gross Margin stood at 94.31% for Q3 2025, which was down 0.20% from 94.50% recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Gross Margin ranged from a high of 96.22% in Q1 2023 and a low of 77.08% during Q4 2024.
  • Moreover, its 3-year median value for Gross Margin was 94.31% (2025), whereas its average is 91.40%.
  • Over the last 5 years, Orchestra BioMed Holdings' Gross Margin had its largest YoY gain of 906bps in 2023, and its largest YoY loss of 1,313bps in 2023.
  • Over the past 4 years, Orchestra BioMed Holdings' Gross Margin (Quarterly) stood at 95.19% in 2022, then slumped by 1,313bps to 82.06% in 2023, then tumbled by 499bps to 77.08% in 2024, then surged by 120bps to 94.31% in 2025.
  • Its last three reported values are 94.31% in Q3 2025, 94.50% for Q2 2025, and 94.93% during Q1 2025.